We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amarin (AMRN) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Amarin (AMRN - Free Report) closed at $19.71 in the latest trading session, marking a -1.99% move from the prior day. This change lagged the S&P 500's daily loss of 0.04%. Meanwhile, the Dow gained 0.26%, and the Nasdaq, a tech-heavy index, lost 0.48%.
Coming into today, shares of the biopharmaceutical company had gained 586.35% in the past month. In that same time, the Medical sector lost 3.8%, while the S&P 500 lost 4.53%.
AMRN will be looking to display strength as it nears its next earnings release, which is expected to be November 7, 2018. The company is expected to report EPS of -$0.09, down 125% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $61.50 million, up 29.86% from the year-ago period.
AMRN's full-year Zacks Consensus Estimates are calling for earnings of -$0.42 per share and revenue of $228.93 million. These results would represent year-over-year changes of -68% and +26.41%, respectively.
It is also important to note the recent changes to analyst estimates for AMRN. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. AMRN currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 86, which puts it in the top 34% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amarin (AMRN) Dips More Than Broader Markets: What You Should Know
Amarin (AMRN - Free Report) closed at $19.71 in the latest trading session, marking a -1.99% move from the prior day. This change lagged the S&P 500's daily loss of 0.04%. Meanwhile, the Dow gained 0.26%, and the Nasdaq, a tech-heavy index, lost 0.48%.
Coming into today, shares of the biopharmaceutical company had gained 586.35% in the past month. In that same time, the Medical sector lost 3.8%, while the S&P 500 lost 4.53%.
AMRN will be looking to display strength as it nears its next earnings release, which is expected to be November 7, 2018. The company is expected to report EPS of -$0.09, down 125% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $61.50 million, up 29.86% from the year-ago period.
AMRN's full-year Zacks Consensus Estimates are calling for earnings of -$0.42 per share and revenue of $228.93 million. These results would represent year-over-year changes of -68% and +26.41%, respectively.
It is also important to note the recent changes to analyst estimates for AMRN. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. AMRN currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 86, which puts it in the top 34% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.